Indoco Remedies' Q3 FY 2025-26 Quarterly Results
- 04 Feb 2026
Result Summary
- Indoco Remedies Ltd reported a 8.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 8.5%.
- Its expenses for the quarter were down by 5.4% QoQ and up 6.3% YoY.
- The net profit increased 219.8% QoQ and increased 3.7% YoY.
- The earnings per share (EPS) of Indoco Remedies Ltd declined at 3.19 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 446.34 | 485.43 | 411.40 | -8.1% | 8.5% |
Total Expenses | 471.50 | 498.43 | 443.35 | -5.4% | 6.3% |
Profit Before Tax | -31.31 | -13.53 | -30.96 | 131.4% | 1.1% |
Tax | -1.86 | -4.32 | -2.56 | -56.9% | -27.3% |
Profit After Tax | -29.45 | -9.21 | -28.40 | 219.8% | 3.7% |
Earnings Per Share | -3.19 | -1.00 | -3.08 | 219.0% | 3.6% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Indoco Remedies Ltd is a well-established Indian pharmaceutical company engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The company operates across various therapeutic segments, including respiratory, anti-infective, dental, gastro-intestinal, pain management, and ophthalmic, among others. Indoco Remedies has a robust presence in both domestic and international markets, exporting its products to over 55 countries. The company is known for its strong focus on research and development to support its product pipeline and enhance its competitive positioning in the pharmaceutical industry. As of the most recent update, there have been no significant public developments affecting the company that have been noted.
Revenue
In the third quarter of fiscal year 2026 (Q3FY26), Indoco Remedies Ltd reported a total income of ₹446.34 crores. This represents a decrease of 8.1% compared to the previous quarter (Q2FY26), where the total income was ₹485.43 crores. However, on a year-over-year basis, there has been an increase of 8.5% from ₹411.40 crores reported in the third quarter of fiscal year 2025 (Q3FY25). The company’s revenue performance demonstrates variability with a notable decline in quarterly income but an overall upward trajectory on an annual basis.
Profitability
For Q3FY26, the financial results show that Indoco Remedies Ltd had a profit before tax of -₹31.31 crores, worsening from -₹13.53 crores in Q2FY26. This marks a quarter-over-quarter increase in losses of 131.4%. Comparatively, the profit before tax in Q3FY25 was -₹30.96 crores, indicating a slight annual increase in losses by 1.1%. The tax expense for Q3FY26 was -₹1.86 crores, a decrease from -₹4.32 crores in Q2FY26 and from -₹2.56 crores in Q3FY25, reflecting a reduction of 56.9% QoQ and 27.3% YoY. The profit after tax for Q3FY26 stood at -₹29.45 crores, a substantial increase in losses from -₹9.21 crores in Q2FY26, representing a 219.8% QoQ increase. Year-over-year, the change is less pronounced, with a 3.7% increase in losses from -₹28.40 crores in Q3FY25. Earnings per share for Q3FY26 was -₹3.19, compared to -₹1.00 in Q2FY26 and -₹3.08 in Q3FY25, indicating a significant quarterly increase of 219.0% and a modest annual increase of 3.6%.
Operating Metrics
The financial data for Q3FY26 reveals total expenses of ₹471.50 crores, which reflects a decrease of 5.4% compared to the previous quarter (Q2FY26) expenses of ₹498.43 crores. Year-over-year, there is an increase of 6.3% from ₹443.35 crores in Q3FY25. The operating metrics indicate that while expenses have reduced on a quarterly basis, they have risen on an annual basis. This data provides insights into the company's cost management and operational efficiency over the analyzed periods.